91 – 100 of 110
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Allvarlig lungsjukdom vid RA och TNF-blockering--finns det ett samband?
(
- Contribution to journal › Article
- 2005
-
Mark
The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
(
- Contribution to journal › Article
-
Mark
Reply
(
- Contribution to journal › Letter
-
Mark
Proposed core set of outcome measures in patients with primary Sjögren's syndrome: 5 year follow up.
(
- Contribution to journal › Article
-
Mark
Assessment of fatigue in primary Sjögren's syndrome: the Swedish version of the Profile of Fatigue.
(
- Contribution to journal › Article
-
Mark
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
(
- Contribution to journal › Article
- 2004
-
Mark
Health status as measured by SF-36 reflects changes and predicts outcome in chronic musculoskeletal pain: a 3-year follow up study in the general population
(
- Contribution to journal › Article